Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trialKevin J. Harrington, J. Guigay, Robert L. Ferris et al.|The Lancet Oncology|2017Cited by 431
Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trialDavid Cella, Robert J. Motzer, Viktor Grünwald et al.|The Lancet Oncology|2016Cited by 219
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor EntitiesNader Hirmas, Wolfgang P. Fendler, Rainer Hamacher et al.|Journal of Nuclear Medicine|2022Cited by 68
Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligenceJulius Keyl, Jens Kleesiek, Ken Herrmann et al.|Nature Cancer|2025Cited by 48
Diagnostic Accuracy of<sup>68</sup>Ga-FAPI Versus<sup>18</sup>F-FDG PET in Patients with Various MalignanciesNader Hirmas, Wolfgang P. Fendler, Rainer Hamacher et al.|Journal of Nuclear Medicine|2024Cited by 31